Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
Year: 2013
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: To estimate the incidence of and to characterize cognitive and imaging findings associated with incident amyloid PET positivity. METHODS: Cognitively normal (CN) participants in the Mayo Clinic Study of Aging who had 2 or more serial imaging assessments, which included amyloid PET, FDG-PET, and MRI at each time point, were eligible for analysis (n = 207). Twelve subjects with Alzheimer disease dementia were included for comparison. RESULTS: Of the 123 CN participants who were amyloid-negative at baseline, 26 met criteria for incident amyloid PET positivity. Compared to the 69 subjects who remained stable amyloid-negative, on average these 26 did not differ on any imaging, demographic, or cognitive variables except amyloid PET (by definition) and task-free functional connectivity, which at baseline was greater in the incident amyloid-positive group. Eleven of the 26 incident amyloid-positive subjects had abnormal hippocampal volume, FDG-PET, or both at baseline. CONCLUSIONS: The incidence of amyloid PET positivity is approximately 13% per year among CN participants over age 70 sampled from a population-based cohort. In 15/26 (58%), incident amyloid positivity occurred prior to abnormalities in FDG-PET and hippocampal volume. However, 11/26 (42%) incident amyloid-positive subjects had evidence of neurodegeneration prior to incident amyloid positivity. These 11 could be subjects with combinations of preexisting non-Alzheimer pathophysiologies and tau-mediated neurodegeneration who newly entered the amyloid pathway. Our findings suggest that both "amyloid-first" and "neurodegeneration-first" biomarker profile pathways to preclinical AD exist.
Source: Neurology
Institution: Mayo Clinic
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Pathological basis of MRS and DTI changes in neurodegenerative dementia, Alzheimers Disease Patient Registry, Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers, Alzheimer's Disease Neuroimaging Initiative, ARIC Neurocognitive Study (ARIC-NCS) Renewal 2 of 5, Genome wide association study of gene expression levels in Alzheimer's disease, EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM, Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients, Dominantly Inherited Alzheimer Network, Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W2157657208
